Severe hemophiliacs require recombinant factor replacement perioperatively to secure hemostasis. Many require placement of a central venous access device for delivery of factor replacement throughout the preschool years. Patients with thrombocytopenia, platelet function defects, von Willebrand disease, or acquired coagulopathy may need blood product replacement and special precautions prior to invasive procedures.
Children with sickle cell disease (SCD) may require splenectomy, cholecystectomy, or adenotonsillectomy and are at risk perioperatively of an acute sickling event.
Leukemic patients often require blood products or growth factor support before surgery and frequently in the operating theater throughout their treatment course for lumbar punctures, bone marrow biopsies, and central venous access-related issues.
Children who are splenectomized are rendered susceptible to overwhelming infection by Gram-positive encapsulated organisms. They require vaccination prior to splenectomy and should receive postoperative antibiotic prophylaxis up to the age of 16. Where possible, splenectomy should be deferred until >6 years of age, although this latter recommendation does not apply to children with SCD, who are functionally asplenic from a young age.
This is a preview of subscription content, log in to check access.
Ai J, Advani A. Current status of antibody therapy in all. Br J Haematol. 2015;168(4):471–80.CrossRefGoogle Scholar
Arcesi RJ, Hann IM, Smith OP. Paediatric haematology. 3rd ed. Oxford: Blackwell Publishing; 2006.CrossRefGoogle Scholar
Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the Feiba Novoseven comparative (Fenoc) study. Blood. 2007;109(2):546–51.CrossRefGoogle Scholar
Blood L-JL. In: Oldham KT, Colombani PM, Foglia RP, Skinner MA, editors. Principles of practice of pediatric surgery. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 297–312.Google Scholar
Bolton-Maggs PHB. D Poles et al. on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2015. Annual SHOT Report (2016). www.shotuk.org/shot-reports/
Bolton-Maggs PH, Stevens RF, Dodd NJ, Lamont G, Tittensor P, King MJ. Guidelines for the diagnosis and management of hereditary spherocytosis. Br J Haematol. 2004;126(4):455–74.CrossRefGoogle Scholar
Bolton-Maggs PH, Chalmers EA, Collins PW, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the Ukhcdo. Br J Haematol. 2006;135(5):603–33.CrossRefGoogle Scholar
Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia. 2008;14(4):671–84.CrossRefGoogle Scholar
Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2009;145(1):24–33.CrossRefGoogle Scholar
McCann S, Foa R, Smith OP, Conneally E. Case-based haematology. Oxford: Blackwell Publishing; 2005.Google Scholar
Newall F, Johnston L, Ignjatovic V, Monagle P. Unfractionated heparin therapy in infants and children. Pediatrics. 2009;123(3):e510–8.CrossRefGoogle Scholar
Oldenburg J, Albert T. Novel products for haemostasis–current status. Haemophilia. 2014;20(Suppl 4):23–8.CrossRefGoogle Scholar
Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–86.CrossRefGoogle Scholar
Raja RA, Schmiegelow K, Frandsen TL. Asparaginase-associated pancreatitis in children. Br J Haematol. 2012;159(1):18–27.CrossRefGoogle Scholar
Rodeghiero F, Ruggeri M. Itp and international guidelines: what do we know, what do we need? Presse Med. 2014;43(4 Pt 2):e61–7.CrossRefGoogle Scholar
Sadelain M, Brentjens R, Rivière I, Park J. CD19 CAR Therapy for Acute Lymphoblastic Leukemia. Am Soc Clin Oncol Educ Book. 2015:e360-3. doi:10.14694/EdBook_AM.2015.35.e360Google Scholar
Smith OP, Hann I. Essential paediatric haematology. London: Martin Dunitz Publishers; 2002.CrossRefGoogle Scholar
Standards for the clinical care of children and adults with thalassaemia in the UK; 2008.Google Scholar
Thachil J, Toh HC, Levi M, Watson HG. The withdrawal of activated protein C from the use in patients with severe sepsis and dic [amendment to the Bcsh guideline on disseminated intravascular coagulation]. Br J Haematol. 2012;157(4):493–4.CrossRefGoogle Scholar
Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033–48.CrossRefGoogle Scholar